CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer
CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer
复制标题
CXCL13表达可预测胃癌患者术后辅助化疗的获益
DOI：
10.1007/s00262-017-2083-y
复制
发表时间：
2018-02-01
影响因子：
5.8
通讯作者：
Xu, Jiejie
中科院分区：
文献类型：
--
作者：
Wei, Yichou;Lin, Chao;Xu, Jiejie
趋化因子(C-X-C基序)配体13(CXCL13/BLC/BCA-1)是C-X-C趋化因子家族中的一种细胞因子，对B细胞具有选择性趋化作用。以往的研究表明，CXCL13的高表达与多种癌症的预后不良有关。然而，CXCL13的表达与胃癌之间的关系仍不清楚。方法采用免疫组织化学方法，采用免疫组织化学方法，对2008年在一家机构随机选择的227例胃癌患者的214例测试集和227例验证集的CXCL13表达进行半定量分析。以中位数作为截断点。我们对CXCL-13的表达与临床病理变量进行相关性分析，Kaplan-Meier分析与总生存期(OS)的关系，并进行多因素模型分析。经多因素分析，CXCL13表达与OS无关，与临床病理因素无关。在T2-4期患者组中，CXCL13的低表达与较长的生存期有关，特别是在接受辅助化疗的患者组(57.6%)。结论CXCL13在肿瘤内的表达可作为判断胃癌术后患者预后的独立指标。此外，CXCL13的表达可作为这些患者术后辅助化疗反应的预测生物标志物。
BackgroundChemokine (C-X-C motif) ligand 13 (CXCL13/BLC/BCA-1) is a cytokine from C-X-C chemokine family, which is selectively chemotactic for B cells. Previous research has demonstrated that high CXCL13 expression is correlated to poor prognosis in various cancers. However, the association between CXCL13 expression and gastric cancer is still unclear.MethodsIntratumoral CXCL13 expression was evaluated by immunohistochemistry using a semi-quantitative method (modified H-score) in a testing set of 214 and a validation set of 227 randomly selected gastric cancer patients resected in 2008 in one institution. The median value was used as the cut-off point. We performed correlative analysis of CXCL-13 expression with clinicopathological variables, Kaplan–Meier analysis for association with overall survival (OS), and multivariate modeling.ResultsHigh CXCL13 expression was associated with larger tumor diameter and shorter OS. By multivariate analysis, CXCL13 expression was associated with OS independently from clinicopathological factors. Within the T2–4 stage patients group, low CXCL13 expression was associated with longer survival, especially in the subgroup of patients (57.6%) who received adjuvant chemotherapy.ConclusionsIntratumoral CXCL13 expression appears as an independent prognostic marker for patients after gastric cancer resection. In addition, CXCL13 expression may serve as a predictive biomarker of response to postoperative adjuvant chemotherapy in these patients.